Sanofi is considering releasing an active pharmaceutical company
A few days after they announced that their
joint vaccine would undergo human clinical trials, Sanofi and GSK started the week with
additional news regarding the vaccine.
Oliver Bogillot, Sanofi’s French CEO,
announced that the vaccine's price would be €10 or less. Despite the announcement, he iterated the fact that the
final price hadn't been set yet.
Besides the price, the Sanofi plans to list
its active pharmaceutical ingredients (API) company publicly. The initial
public offering is scheduled to happen in the following months, and the new
business could be valued at up to €2billion.
It is the embodiment of a plan touted in
February, through which Sanofi will create a standalone company by reuniting
under the same roof its commercial and development activities and the power of
its six European production sites.
According to Sanofi, the move would balance
the industry's reliance on Asia for ingredients, which lately has been
disrupted by the pandemic. The drugmaker said that it is taking into
consideration a 2022 Euronext Paris listing. If it does it, the new API would
be the second-largest in the world after the Swiss Lonza.
Following the news, Sanofi stock price
gained 2%.
Sources:
marketwatch.com, finance.yahoo.com
This information is prepared for general circulation. It does not regard to the specific investment objectives, financial situation or the particular needs of any recipient.
You should independently evaluate each financial product and consider the suitability of such a financial product, by taking into account your specific investment objectives, financial situation or particular needs, and by consulting an independent financial adviser as needed, before dealing in any financial products mentioned in this document.
This information may not be published, circulated, reproduced or distributed in whole or in part to any other person without the Company’s prior written consent. Past performance is not always indicative of likely or future performance. Any views or opinions presented are solely those of the author and do not necessarily represent those of za.capex.com
JME Financial Services (Pty) Ltd trading as ZA.CAPEX.COM acts as intermediary between the investor and Magnasale Trading Ltd, the counterparty to the contract for difference purchased by the Investor via ZA.CAPEX.COM, authorised & regulated by the Cyprus Securities and Exchange Commission with license number 264/15. Magnasale Trading Ltd is the principal to the CFD purchased by investors.
